360 related articles for article (PubMed ID: 29235549)
1. Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends.
van Rossum PSN; Mohammad NH; Vleggaar FP; van Hillegersberg R
Nat Rev Gastroenterol Hepatol; 2018 Apr; 15(4):235-249. PubMed ID: 29235549
[TBL] [Abstract][Full Text] [Related]
2. Surgical and multimodal treatment of metastatic oesophageal cancer: retrospective cohort study.
Knipper K; Lemties J; Krey T; Lyu SI; Wirsik NM; Schiffmann LM; Fuchs HF; Gebauer F; Schröder W; Popp FC; Quaas A; Schlößer HA; Bruns CJ; Schmidt T
BJS Open; 2024 May; 8(3):. PubMed ID: 38814750
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in patients with oesophageal cancer: analysis at different steps of the treatment pathway.
Scarpa M; Saadeh LM; Fasolo A; Alfieri R; Cagol M; Cavallin F; Pinto E; Zaninotto G; Ancona E; Castoro C
J Gastrointest Surg; 2013 Mar; 17(3):421-33. PubMed ID: 23297025
[TBL] [Abstract][Full Text] [Related]
4. Multidisciplinary approach for patients with esophageal cancer.
Villaflor VM; Allaix ME; Minsky B; Herbella FA; Patti MG
World J Gastroenterol; 2012 Dec; 18(46):6737-46. PubMed ID: 23239911
[TBL] [Abstract][Full Text] [Related]
5. T1N0 oesophageal cancer: patterns of care and outcomes over 25 years.
Kamel MK; Lee B; Rahouma M; Harrison S; Nguyen AB; Port JL; Altorki NK; Stiles BM
Eur J Cardiothorac Surg; 2018 May; 53(5):952-959. PubMed ID: 29244113
[TBL] [Abstract][Full Text] [Related]
6. Recent progress in multidisciplinary treatment for patients with esophageal cancer.
Watanabe M; Otake R; Kozuki R; Toihata T; Takahashi K; Okamura A; Imamura Y
Surg Today; 2020 Jan; 50(1):12-20. PubMed ID: 31535225
[TBL] [Abstract][Full Text] [Related]
7. Nrf2 promotes oesophageal cancer cell proliferation via metabolic reprogramming and detoxification of reactive oxygen species.
Kitano Y; Baba Y; Nakagawa S; Miyake K; Iwatsuki M; Ishimoto T; Yamashita YI; Yoshida N; Watanabe M; Nakao M; Baba H
J Pathol; 2018 Mar; 244(3):346-357. PubMed ID: 29243822
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
[TBL] [Abstract][Full Text] [Related]
9. Is chemotherapy for advanced or metastatic oesophageal squamous cell carcinoma no longer needed?
van Laarhoven HW
Lancet Oncol; 2020 Jun; 21(6):743-745. PubMed ID: 32502437
[No Abstract] [Full Text] [Related]
10. Palliative Management of Gastric and Esophageal Cancer.
Halpern AL; McCarter MD
Surg Clin North Am; 2019 Jun; 99(3):555-569. PubMed ID: 31047042
[TBL] [Abstract][Full Text] [Related]
11. Role of Esophageal Metal Stents Placement and Combination Therapy in Inoperable Esophageal Carcinoma: A Systematic Review and Meta-analysis.
Lai A; Lipka S; Kumar A; Sethi S; Bromberg D; Li N; Shen H; Stefaniwsky L; Brady P
Dig Dis Sci; 2018 Apr; 63(4):1025-1034. PubMed ID: 29417326
[TBL] [Abstract][Full Text] [Related]
12. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
Kojima T; Shah MA; Muro K; Francois E; Adenis A; Hsu CH; Doi T; Moriwaki T; Kim SB; Lee SH; Bennouna J; Kato K; Shen L; Enzinger P; Qin SK; Ferreira P; Chen J; Girotto G; de la Fouchardiere C; Senellart H; Al-Rajabi R; Lordick F; Wang R; Suryawanshi S; Bhagia P; Kang SP; Metges JP;
J Clin Oncol; 2020 Dec; 38(35):4138-4148. PubMed ID: 33026938
[TBL] [Abstract][Full Text] [Related]
13. Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study.
Hagens ERC; van Berge Henegouwen MI; van Sandick JW; Cuesta MA; van der Peet DL; Heisterkamp J; Nieuwenhuijzen GAP; Rosman C; Scheepers JJG; Sosef MN; van Hillegersberg R; Lagarde SM; Nilsson M; Räsänen J; Nafteux P; Pattyn P; Hölscher AH; Schröder W; Schneider PM; Mariette C; Castoro C; Bonavina L; Rosati R; de Manzoni G; Mattioli S; Garcia JR; Pera M; Griffin M; Wilkerson P; Chaudry MA; Sgromo B; Tucker O; Cheong E; Moorthy K; Walsh TN; Reynolds J; Tachimori Y; Inoue H; Matsubara H; Kosugi SI; Chen H; Law SYK; Pramesh CS; Puntambekar SP; Murthy S; Linden P; Hofstetter WL; Kuppusamy MK; Shen KR; Darling GE; Sabino FD; Grimminger PP; Meijer SL; Bergman JJGHM; Hulshof MCCM; van Laarhoven HWM; Mearadji B; Bennink RJ; Annema JT; Dijkgraaf MGW; Gisbertz SS
BMC Cancer; 2019 Jul; 19(1):662. PubMed ID: 31272485
[TBL] [Abstract][Full Text] [Related]
14. Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis.
van Kleef JJ; Ter Veer E; van den Boorn HG; Schokker S; Ngai LL; Prins MJ; Mohammad NH; van de Poll-Franse LV; Zwinderman AH; van Oijen MGH; Sprangers MAG; van Laarhoven HWM
J Natl Cancer Inst; 2020 Jan; 112(1):12-29. PubMed ID: 31251346
[TBL] [Abstract][Full Text] [Related]
15. Emerging Multimodality Approaches to Treat Localized Esophageal Cancer.
Kelly RJ
J Natl Compr Canc Netw; 2019 Aug; 17(8):1009-1014. PubMed ID: 31390584
[TBL] [Abstract][Full Text] [Related]
16. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
Ajani JA; D'Amico TA; Bentrem DJ; Chao J; Corvera C; Das P; Denlinger CS; Enzinger PC; Fanta P; Farjah F; Gerdes H; Gibson M; Glasgow RE; Hayman JA; Hochwald S; Hofstetter WL; Ilson DH; Jaroszewski D; Johung KL; Keswani RN; Kleinberg LR; Leong S; Ly QP; Matkowskyj KA; McNamara M; Mulcahy MF; Paluri RK; Park H; Perry KA; Pimiento J; Poultsides GA; Roses R; Strong VE; Wiesner G; Willett CG; Wright CD; McMillian NR; Pluchino LA
J Natl Compr Canc Netw; 2019 Jul; 17(7):855-883. PubMed ID: 31319389
[TBL] [Abstract][Full Text] [Related]
17. The role of palliative interventional radiotherapy (brachytherapy) in esophageal cancer: An AIRO (Italian Association of Radiotherapy and Clinical Oncology) systematic review focused on dysphagia-free survival.
Lancellotta V; Cellini F; Fionda B; De Sanctis V; Vidali C; Fusco V; Barbera F; Gambacorta MA; Corvò R; Magrini SM; Tagliaferri L
Brachytherapy; 2020; 19(1):104-110. PubMed ID: 31636025
[TBL] [Abstract][Full Text] [Related]
18. Treatment Outcomes and Prognostic Factors After Recurrence of Esophageal Squamous Cell carcinoma.
Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
World J Surg; 2018 Jul; 42(7):2190-2198. PubMed ID: 29285608
[TBL] [Abstract][Full Text] [Related]
19. KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma.
Shah MA; Bennouna J; Doi T; Shen L; Kato K; Adenis A; Mamon HJ; Moehler M; Fu X; Cho BC; Bordia S; Bhagia P; Shih CS; Desai A; Enzinger P
Future Oncol; 2021 Apr; 17(10):1143-1153. PubMed ID: 33533655
[TBL] [Abstract][Full Text] [Related]
20. Esophageal carcinoma: Towards targeted therapies.
Fatehi Hassanabad A; Chehade R; Breadner D; Raphael J
Cell Oncol (Dordr); 2020 Apr; 43(2):195-209. PubMed ID: 31848929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
